Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Management standards for stable coronary artery disease in India.

Mishra S, Ray S, Dalal JJ, Sawhney JP, Ramakrishnan S, Nair T, Iyengar SS, Bahl VK.

Indian Heart J. 2016 Dec;68 Suppl 3:S31-S49. doi: 10.1016/j.ihj.2016.11.320.

2.

Management Protocols of stable coronary artery disease in India: Executive summary.

Mishra S, Ray S, Dalal JJ, Sawhney JP, Ramakrishnan S, Nair T, Iyengar SS, Bahl VK.

Indian Heart J. 2016 Nov - Dec;68(6):868-873. doi: 10.1016/j.ihj.2016.11.318. No abstract available.

3.
4.

The active modulation of drug release by an ionic field effect transistor for an ultra-low power implantable nanofluidic system.

Bruno G, Canavese G, Liu X, Filgueira CS, Sacco A, Demarchi D, Ferrari M, Grattoni A.

Nanoscale. 2016 Nov 10;8(44):18718-18725.

PMID:
27787528
5.
6.

The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo.

Messerli FH, Toklu B, Fakheri R, Bangalore S.

Ann Transl Med. 2016 Aug;4(16):321. doi: 10.21037/atm.2016.08.11. No abstract available.

8.

Recent advances in pathogenesis, assessment, and treatment of atherosclerosis.

Spence JD.

F1000Res. 2016 Jul 28;5. pii: F1000 Faculty Rev-1880. doi: 10.12688/f1000research.8459.1. Review.

9.

Stabilization of high-risk plaques.

Takata K, Imaizumi S, Zhang B, Miura S, Saku K.

Cardiovasc Diagn Ther. 2016 Aug;6(4):304-21. doi: 10.21037/cdt.2015.10.03. Review.

10.

Mitochondrial uncoupling proteins regulate angiotensin-converting enzyme expression: crosstalk between cellular and endocrine metabolic regulators suggested by RNA interference and genetic studies.

Dhamrait SS, Maubaret C, Pedersen-Bjergaard U, Brull DJ, Gohlke P, Payne JR, World M, Thorsteinsson B, Humphries SE, Montgomery HE.

Inside Cell. 2016 Jan;1(1):70-81.

11.

Adding carotid total plaque area to the Framingham risk score improves cardiovascular risk classification.

Perez HA, Garcia NH, Spence JD, Armando LJ.

Arch Med Sci. 2016 Jun 1;12(3):513-20. doi: 10.5114/aoms.2016.59924.

12.

ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.

Saleem TS, Bharani K, Gauthaman K.

Open Access Emerg Med. 2010 Jul 1;2:51-9. Review.

13.

Renin-Angiotensin System Genes Polymorphisms and Long-Term Prognosis in Taiwanese Patients with Hypertension and Coronary Artery Disease.

Wu CK, Lee JK, Lin LY, Huang YT, Hwang JJ, Lin CL, Tseng CD, Chiang FT.

Acta Cardiol Sin. 2013 Jan;29(1):28-36.

14.

Angiotensin-Converting Enzyme in Smooth Muscle Cells Promotes Atherosclerosis-Brief Report.

Chen X, Howatt DA, Balakrishnan A, Moorleghen JJ, Wu C, Cassis LA, Daugherty A, Lu H.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1085-9. doi: 10.1161/ATVBAHA.115.307038.

PMID:
27055902
15.

Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.

Oemrawsingh RM, Akkerhuis KM, Van Vark LC, Redekop WK, Rudez G, Remme WJ, Bertrand ME, Fox KM, Ferrari R, Danser AH, de Maat M, Simoons ML, Brugts JJ, Boersma E; PERGENE investigators..

J Am Heart Assoc. 2016 Mar 28;5(3):e002688. doi: 10.1161/JAHA.115.002688.

16.

2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension.

Shin J, Park JB, Kim KI, Kim JH, Yang DH, Pyun WB, Kim YG, Kim GH, Chae SC; Guideline Committee of the Korean Society of Hypertension..

Clin Hypertens. 2015 Apr 8;21:2. doi: 10.1186/s40885-014-0013-2. Review.

17.
18.

Executive Summary of the Guidelines on Stable Coronary Disease.

César LA, Mansur Ade P, Ferreira JF.

Arq Bras Cardiol. 2015 Oct;105(4):328-38. doi: 10.5935/abc.20150136. English, Portuguese. No abstract available.

19.

Understanding and treating hypertension in diabetic populations.

Volpe M, Battistoni A, Savoia C, Tocci G.

Cardiovasc Diagn Ther. 2015 Oct;5(5):353-63. doi: 10.3978/j.issn.2223-3652.2015.06.02. Review.

20.

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.

Chien SC, Ou SM, Shih CJ, Chao PW, Li SY, Lee YJ, Kuo SC, Wang SJ, Chen TJ, Tarng DC, Chu H, Chen YT.

Medicine (Baltimore). 2015 Oct;94(43):e1751. doi: 10.1097/MD.0000000000001751.

Items per page

Supplemental Content

Support Center